The present study aimed to formulate orodispersible tablets of deferasirox to increase its solubility and to enhance the patient compliance, provide a quick onset of action, as compared to marketed formulations. Dispersible tablets are easier to administer or swallow than capsule for pediatrics, dysphasic patients, mentally ill, uncooperative and nauseated patients, those with conditions of motion sickness sudden episodes of allergic attacks or coughing. Deferasirox is indicated for treatment of chronic iron overloaded caused by blood transfusion patients with Myelodysplastic syndrome, sickle cell diseases, beta-thalassemia and other anemia. Orodispersible tablets were prepared by direct compression technique using 3 different superdisintegrants like as crospovidone, croscarmellose sodium and sodium starch glycolate. The prepared powder mixtures were subjected to both pre and post compression evaluation parameters including; IR spectroscopy, tablet hardness, friability, wetting time, disintegration time and in-vitro drug release. IR studies indicated that there was no interaction between the drug and excipients. Tablet hardness and friability indicated good mechanical strength of tablets. Wetting time decreased from 59 to 53 sec by increasing the superdisintegrants concentration from 4% to 12% w/w of tablets. The F9 formulation which was prepared by using the 12% of crospovidone showed the increase the drug release rate from 47.69±0.02 to 99.45±0.05% after 20 min. The F9 formulation with disintegration time 124 sec and dissolution rate 99.45±0.05 was selected as best formulation. Formulation F9 compared with conventional marketed formulation and F9 formulation was found to be superior.
Loading....